Robert Parangi, MD
Internal Medicine · Paramus, NJNPI 1528131281
Payments from drug & device makers
Across 146 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$604
- GSK$424
- Pfizer$348
- Braeburn Inc.$195
- Bayer$125
- Intra-sana Laboratories$120
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,01098%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $604 |
| GSK | 8 | $424 |
| Pfizer | 21 | $348 |
| Braeburn Inc. | 12 | $195 |
| Bayer | 1 | $125 |
| Intra-sana Laboratories | 1 | $120 |
| AstraZeneca | 1 | $116 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $90 |
| Lilly USA, LLC | 5 | $80 |
| Collegium Pharmaceutical, Inc. | 6 | $79 |
| Biodelivery Sciences International, Inc. | 1 | $76 |
| Redhill Biopharma Inc. | 1 | $71 |
| Exact Sciences | 3 | $66 |
| Novo Nordisk | 4 | $66 |
| Cumberland Pharmaceuticals, Inc. | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Amgen | 4 | $51 |
| Novartis | 3 | $49 |
| Averitas Pharma Inc. | 1 | $46 |
| Emergent Biosolutions Inc. | 1 | $45 |
| GRT US Holding, Inc. | 1 | $45 |
| Gilead | 2 | $41 |
| Daiichi Sankyo Inc. | 3 | $41 |
| Boston Scientific | 1 | $30 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Baudax Bio Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $14 |
| Global Blood Therapeutics, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Protega Pharmaceutials Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Virtus Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ANORO$351
- Kerendia$125
- UBRELVY$125
- Reltone 200 Mg$120
- GLYCATE$120
- Reltone 400 Mg$120
- LOKELMA$116
How this compares
$3,057 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 395 | $133,451 |
| JanuviaSitagliptin Phosphate | 110 | $46,662 |
| MounjaroTirzepatide | 38 | $42,361 |
| Invega SustennaPaliperidone Palmitate | 11 | $26,891 |
| SantylCollagenase Clostridium Hist. | 81 | $26,655 |
| OzempicSemaglutide | 25 | $23,589 |
| Risperidone ErRisperidone Microspheres | 21 | $22,153 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 70 | $20,890 |
| OxycontinOxycodone Hcl | 16 | $19,227 |
| MyrbetriqMirabegron | 77 | $18,930 |
| XareltoRivaroxaban | 45 | $18,050 |
| Enoxaparin Sodium | 52 | $12,049 |
| Repatha SureclickEvolocumab | 15 | $10,820 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $10,643 |
| Divalproex Sodium | 162 | $9,371 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $348 | $133,451395 claims |
| Lilly USA, LLCMounjaro, Trulicity | $80 | $51,00071 claims |
| Novo NordiskOzempic, Tresiba, Novolog | $66 | $32,211100 claims |
| GSKArexvy | $424 | $20,89070 claims |
| Boehringer IngelheimJardiance, Tradjenta | $19 | $16,97557 claims |
| AbbVieLumigan | $604 | $6,43114 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $79 | $5,49635 claims |
| AstraZenecaBevespi Aerosphere | $116 | $5,13111 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $3,55135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Paramus
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.